UPDATE: Jefferies Starts Cincor Pharma Inc (CINC) at Buy

February 1, 2022 3:52 AM EST
Get Alerts CINC Hot Sheet
Price: $28.89 -0.14%

Rating Summary:
    4 Buy, 3 Hold, 0 Sell

Rating Trend: Down Down

Today's Overall Ratings:
    Up: 17 | Down: 32 | New: 11
Join SI Premium – FREE
(Updated - February 1, 2022 4:52 AM EST)

Jefferies analyst Dennis Ding initiates coverage on Cincor Pharma Inc (NASDAQ: CINC) with a Buy rating and a price target of $30.00.

The analyst comments "CINC has a differentiated pill, CIN-107, for difficult to treat high blood pressure in Phase II, plus a slew of other indications, also with blockbuster potential, in Phase I/II. We believe there is a rich catalyst path over the next 12-18 months and, with continued derisking, this could drive the stock towards a $1B+ market cap with long-term M&A optionality, too. Initiate at Buy."

For an analyst ratings summary and ratings history on Cincor Pharma Inc click here. For more ratings news on Cincor Pharma Inc click here.

Shares of Cincor Pharma Inc closed at $19.07 yesterday.

You May Also Be Interested In

Related Categories

Analyst Comments, New Coverage

Related Entities

Jefferies & Co